Page 319«..1020..318319320321..330340..»

Engineers develop new tool that will allow for more personalized cell therapies – UMN News

Posted: July 27, 2022 at 2:33 am

A University of Minnesota Twin Cities team has developed a new tool to predict and customize the rate of a specific kind of DNA editing called site-specific recombination. The research, recently published in Nature Communications,paves the way for more personalized, efficient genetic and cell therapies for diseases such as diabetes and cancer.

The process of site-specific recombination involves using enzymes that recognize and modify specific sequences of DNA in living cells. It has important applications in cellular therapies used to treat myriad diseases.

U of M engineers developed a method that makes the site-specific recombination process more efficient and predictable. The model allows researchers to program the rate at which the DNA is edited, which means they can control the speed at which a therapeutic cell responds to its environment, thereby controlling how quickly or slowly it produces a drug or therapeutic protein.

To our knowledge, this is the first example of using a model to predict how modifying a DNA sequence can control the rate of site-specific recombination, said Casim Sarkar, senior author on the paper and an associate professor in the U of M Department of Biomedical Engineering. By applying engineering principles to this problem, we can dial in the rate at which DNA editing happens and use this form of control to tailor therapeutic cellular responses. Our study also identified novel DNA sequences that are much more efficiently recombined than those found in nature, which can accelerate cellular response times.

Sarkar and his team first developed an experimental method to calculate the rate of site-specific recombination, then used that information to train a machine learning algorithm. Ultimately, this allows the researchers to simply type in a DNA sequence and have the model predict the rate at which that DNA sequence will be recombined.

They also found that they could use modeling to predict and control the simultaneous production of multiple proteins within a cell. This could be used to program stem cells to produce new tissues or organs for regenerative medicine applications or to endow therapeutic cells with the ability to produce multiple drugs in pre-defined proportions.

This research was funded by the National Institutes of Health.

-30-

About the College of Science and EngineeringThe University of Minnesota College of Science and Engineering brings together the Universitys programs in engineering, physical sciences, mathematics and computer science into one college. The college is ranked among the top academic programs in the country and includes 12 academic departments offering a wide range of degree programs at the baccalaureate, master's, and doctoral levels. Learn more at cse.umn.edu.

Read the original here:
Engineers develop new tool that will allow for more personalized cell therapies - UMN News

Posted in Minnesota Stem Cells | Comments Off on Engineers develop new tool that will allow for more personalized cell therapies – UMN News

University of Minnesota scientist responds to fraud allegations in Alzheimer’s research – Star Tribune

Posted: July 27, 2022 at 2:33 am

A senior University of Minnesota scientist said it is "devastating" that a colleague might have doctored images to prop up research, but she defended the authenticity of her groundbreaking work on the origins of Alzheimer's disease.

Dr. Karen Ashe declined to comment about a U investigation into the veracity of studies led by Sylvain Lesn, a neuroscientist she hired and a rising star in the field of Alzheimer's research. However, she criticized an article in Science magazine that raised concerns this week about Lesn, because she said it confused and exaggerated the effect the U's work had on downstream drug development to treat Alzheimer's-related dementia.

"Having worked for decades to understand the cause of Alzheimer disease, so that better treatments can be found for patients, it is devastating to discover that a co-worker may have misled me and the scientific community through the doctoring of images," Ashe said in an e-mail Friday morning. "It is, however, additionally distressing to find that a major scientific journal has flagrantly misrepresented the implications of my work."

Questions have surfaced about as many as 10 papers written by Lesn, and often coauthored by Ashe and other U scientists, and whether they used manipulated or duplicated images to inflate the role of a protein in the onset of Alzheimer's.

The Science article detailed efforts by Dr. Matthew Schrag, an Alzheimer's researcher in Tennessee, who colorized and magnified images from Lesn's studies in ways that revealed questions about whether they were doctored or copied. Expert consultants agreed in the article that some of the images in the U studies appeared manipulated in ways that elevated the importance of a protein called A*56.

Many of the images were of Western blot tests showing that A*56, also called amyloid beta star 56, was more prevalent in mice that were older and showed signs of memory loss.

The U studies have been so influential on the course of Alzheimer's research over the past two decades that any evidence of manipulation or false study results could fundamentally shift thinking on the causes of the disease and dementia. The investigation also implicates two successful researchers on a key measure by which they are judged: their ability to pull in federal grants.

Lesn was a named recipient of $774,000 in National Institutes of Health grants specifically involving A*56 from 2008 through 2012. He subsequently received more than $7 million in additional NIH grants related to the origins of Alzheimer's.

Lesn, who did not reply to an e-mail asking for comment, came to the U in 2002 as a postdoctoral research associate after earning his doctorate at the University of Caen Normandy. He took charge of his own U lab by 2009 and became associate director of graduate studies in the neuroscience program in 2020. He was the first- or last-named author on all of the disputed studies, meaning he either instigated the research or was the senior scientist overseeing the work.

Ashe said there are two classes of A proteins, which she refers to as Abeta, and that her efforts have focused on one while drugmakers have unsuccessfully targeted the other with potential Alzheimer's treatments. As a result, she said it was unfair of the Science article even as it raised concerns about research improprieties to pin an entire industry's lack of progress on the scrutinized U research.

"It is this latter form that drug developers have repeatedly but unsuccessfully targeted," she said. "There have been no clinical trials targeting the type 1 form of Abeta, the form which my research has suggested is more relevant to dementia. [The article] has erroneously conflated the two forms of Abeta."

The scientific journal Nature is reviewing a 2006 study led by Lesn regarding the existence and role of A*56 and urging people to use it cautiously for now. Concerns emerged in part because researchers at other institutions struggled to replicate the results.

Two other 2012 and 2013 papers were corrected earlier this year, with U researchers acknowledging errant images but stating that they didn't affect the overall conclusions. However, Schrag said he has concerns the corrected images also were manipulated.

"I think those corrected images are quite problematic," he said.

Beneath the research controversy is a fundamental search and debate over the causes of Alzheimer's and related dementia. One theory is that certain Abeta proteins result in the development of amyloid plaques, which clog up space between nerve cells in the brain and inhibit memory and cognition. Another is that tau proteins clump inside the brain's thinking cells and disrupt them.

Ashe's research has explored both possibilities. Since 1986, she has been a named recipient of more than $28 million in NIH grants, making her one of the most productive researchers in U history.

Complicated legacy

Despite a remarkable history of life-saving inventions and surgical accomplishments, the U also has a legacy of research stars being implicated in scandals.

The late Dr. S. Charles Schulz stepped down as U psychiatry chair in 2015 amid claims by a grieving family that their son, who died by suicide, was coercively recruited into a schizophrenia drug trial.

Duplicated images and errors forced the correction of a 2002 Nature study, led by Dr. Catherine Verfaillie, claiming that certain adult stem cells possessed flexible abilities to grow and develop other cell types.

The late Dr. John Najarian was a pioneer in organ transplantation who elevated the U's global profile, but he faced federal sanctions in the 1990s related to illicit sales of an experimental anti-rejection medication that improved transplant outcomes.

A U investigation of Lesn's work will follow its standard policy of research misconduct allegations, according to a statement from the medical school.

Read more from the original source:
University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune

Posted in Minnesota Stem Cells | Comments Off on University of Minnesota scientist responds to fraud allegations in Alzheimer’s research – Star Tribune

Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes – UCSF

Posted: July 27, 2022 at 2:33 am

Loren and Mike Gordon. Image by Sonya Yruel

A personal investigation into the lifelong implications of his type 1 diabetes (T1D) culminated in a $7 million gift from Mike Gordon, co-founder of Meritech Capital Partners, and his wife, Loren, to help UCSF surmount a key impediment to treating the disease. The funds will support world-class stem cell biologists, immunologists, and bioengineers who are working to overcome significant barriers to beta-cell replacement therapy as an effective treatment for T1D.

Diagnosed when he was just 22 months old, Gordon went through a whole pancreas transplant at UCSF nearly 12 years ago. As a result, he has fewer complications from T1D but must take immunosuppressant drugs and endure the health risks that come with them for the rest of his life.

We wanted to give these researchers freedom to explore bold ideas.

Mike Gordon

Ive suffered a lot from this disease, Gordon said. People say, Its not that bad. Its a chronic condition. But you can fall apart.

Some 1.6 million people in the US have T1D, a disease that is often disabling and can become life-threatening. Diagnoses typically occur in childhood, but not always. The disease develops when the patients immune system attacks its own beta cells, which make insulin in the pancreas. The resulting lack of insulin leaves the body unable to absorb sugar from the bloodstream and convert it into energy, so sugar builds up in the blood. Patients are subject to a lifelong dependence on insulin and are at a higher risk for heart disease, blindness, kidney failure, and other chronic conditions, in addition to shortened average life expectancy.

Beta cell-replacement therapy has shown enormous promise for T1D patients. Beta cells make up 50%-70% of the cells in human pancreatic islets groups of cells in the pancreas that produce blood glucose-regulating hormones and they are the sole producers of insulin in the body. However, replacement beta cells dont live long, and the immune system often rejects the ones that do survive. To prevent the immune system from attacking the replacement cells, immunosuppressants are necessary, but they can be toxic and leave patients vulnerable to malignancies and other infections. UCSF scientists are poised to find solutions to these challenges.

So often the NIH provides funds for low-risk projects where outcomes are more predictable, Gordon said. We didnt want that; we wanted to give these researchers freedom to explore bold ideas.

The research team will use the Gordons investment to help answer two big questions: How can they prolong the survival of replacement beta cells after transplantation? And, can the need for patients to take immunosuppressive drugs be eliminated? The answers to these questions will be a game-changer for patients around the world.

Four interdisciplinary investigators will lead the research:

Julie B. Sneddon, PhDAssistant professor in the UCSF Diabetes Center, the UCSF Broad Center of Regeneration Medicine and Stem Cell Research, and the UCSF Department of Cell and Tissue Biology

Currently, islet-cell replacement relies on obtaining pancreatic tissue from deceased human donors. Thanks to groundbreaking advances during the last decade, beta cells can now be laboratory-generated from pluripotent stem cells, which means supplies, in theory, are unlimited. This creates an opportunity to engineer the stem cell-derived beta cells in ways that support their survival and help them avoid attack by the immune system.

We used to say we were 10 years away from a cure for T1D. We still might be. But if you look at the advances in cell biology and immunology, we have the road map now, Parent said.

Over the past five years, Drs. Parent, Tang, Sneddon, and Desai have co-advised trainees, joined forces on numerous projects, and published papers together. Their labs combine the fresh perspectives and innovation of junior faculty members with the expertise and experience of senior faculty members. The groups collective knowledge, unique understanding, and productive ongoing collaborations position them as an effective group to take on this challenge.

Insulin was first used to successfully treat a patient with type 1 diabetes a century ago, but it wasnt until 1980 that two Minnesota surgeons demonstrated successful intraportal islet transplantation in 10 patients with surgically induced diabetes (in which the patients own islet cells, or autografts, were infused back into their bodies after islet isolation). Ultimately, three of those patients achieved insulin independence for one, nine, and 38 months, respectively. In the last decade, significant strides have been made in groundbreaking technologies such as immunotherapy, metabolomics, and genomics. UCSF has been at the forefront of these advances, especially in immunology, with the Bakar ImmunoX initiative driving collaborative science and the UCSF Helen Diller Family Comprehensive Cancer Center using immunotherapies to find cures for some cancer patients.

All this progress has positively impacted diabetes research. Mark Anderson, MD, PhD, the Robert B. Friend and Michelle M. Friend Professor of Diabetes Research and the new director of the UCSF Diabetes Center, is optimistic about this moment in time and what it means for our patients with T1D and other diseases.

These developments provide unique opportunities for physician-scientists to research the molecular causes of diseases like T1D and potentially replace damaged tissues and repair malfunctioning organs, Anderson said.

Anderson believes that UCSF is one of the few places in the world capable of assembling this type of collaborative team. We are so fortunate to have the Gordons support and shared vision to help us realize the potential of cell transplantation without immune suppression, which could completely change the lives of those affected by T1D.

Read more from the original source:
Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes - UCSF

Posted in Minnesota Stem Cells | Comments Off on Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes – UCSF

Why Are There so Many Books and Shows About Cannibalism? – The New York Times

Posted: July 27, 2022 at 2:31 am

An image came to Chelsea G. Summers: a boyfriend, accidentally on purpose hit by a car, some quick work with a corkscrew and his liver served Tuscan style, on toast.

That figment of her twisted imagination is what prompted Ms. Summers to write her novel, A Certain Hunger, about a restaurant critic with a taste for (male) human flesh.

Turns out, cannibalism has a time and a place. In the pages of some recent stomach-churning books, and on television and film screens, Ms. Summers and others suggest that that time is now.

There is Yellowjackets, a Showtime series about a high school womens soccer team stranded in the woods for a few months too many, which premiered in November. The film Fresh, released on Hulu in March, involves an underground human meat trade for the rich.

Lapvona, Ottessa Moshfeghs novel published in June, portrays cannibalism in a medieval village overcome by plague and drought. Agustina Bazterricas book Tender Is the Flesh, released in English in 2020 and in Spanish in 2017, imagines a future society that farms humans like cattle. Also out in 2017, Raw, a film by the director and screenwriter Julia Ducournau, tells the story of a vegetarian veterinary student whose taste for meat escalates after consuming raw offal.

Still to come is Bones and All, starring Timothe Chalamet. The movie, about a young love that becomes a lust for human consumption, is expected to be released later this year or early next. Its director, Luca Guadagnino, has called the story extremely romantic.

A fascination with cannibalism, perhaps not surprisingly, can toe a fine line, as Ms. Summers learned while writing A Certain Hunger.

When fact checkers came calling about the frenzied scenes in which the books antiheroine prepares her murdered lovers with grotesque, epicurean flourish, their queries about the intricacies of human butchery left Ms. Summers so disturbed that she went full raw vegan for two weeks. The creator was horrified by her own monster.

Publishers may have been, too. When Ms. Summers, who uses a pseudonym, was shopping the book around in 2018, it was rejected more than 20 times before Audible and the Unnamed Press made an offer.

If she were selling A Certain Hunger today, Ms. Summers, who is 59 and lives in New York and Stockholm, believes it would be easier. God bless Yellowjackets, she said in a Zoom interview, which was later interrupted by her dog, Bob, vomiting in the background.

Released in December 2020, her book started to experience a boom in popularity on social media the actress Anya Taylor-Joy posted about it on Instagram, and it received many plaudits in the corner of TikTok known as BookTok about a year later, around the time that Yellowjackets debuted on Showtime.

The pilot episode of Yellowjackets shows a teenage girl getting trapped, bled out like a deer and served on a platter in a terrifying ritual. Bloodthirsty fans continue to dissect the scene on Reddit, where a subreddit message board dedicated to the series has more than 51,000 members.

The shows tension is in the knowledge that you know cannibalism is coming, but when? And why?

The creators of Yellowjackets, Ashley Lyle and Bart Nickerson, who live in Los Angeles, say they wanted the plot to hint that human consumption wasnt merely for the characters survival. This not only adds a spine-tingling creepiness to the already dark story about the soccer team stranded in the wilderness, but also separates it from the real-life tale of a Uruguayan rugby team trapped in the Andes in 1972, whose members resorted to cannibalism to survive. (That event was later dramatized in a 1993 movie, Alive, starring Ethan Hawke.)

I think were often drawn to the things that repulse us the most, Ms. Lyle, 42, said. Mr. Nickerson, 43, chimed in: But I keep coming back to this idea of, what portion of our revulsion to these things is a fear of the ecstasy of them?

Lapvona, by Ms. Moshfegh, is also not overtly cannibalistic; unlike A Certain Hunger, theres no braising with bouquet garni. But one scene involving a toenail is harrowing.

Known for her unsettling, delving-into-the-darkness stories including Eileen and My Year of Rest and Relaxation, Ms. Moshfegh, 41, who lives in Los Angeles, wrote Lapvona during the spring of 2020, in the early days of the pandemic. I wrote it in such complete isolation that I felt this incredible freedom to go wherever I was being led, she said.

The character who eats another human, the greatest sin in his religiously vegetarian village, does so in an act of depraved desperation, said Ms. Moshfegh, a vegetarian herself.

Bill Schutt, the author of Cannibalism: A Perfectly Natural History, says that fictional plots about eating human flesh are as old as literature itself.

When you take something that is so horrible and put it through this lens of fictionalization, he said, we get charged up about it, but we know were safe. At least most of the time: Dr. Schutt only made it halfway through Hulus Fresh before he had to stop the movie. It was almost too well done, he said.

But as his book documents, cannibalism has occurred around the world throughout history, lending these fictional tales a queasy whiff of what if?

Historical examples in the book include mumia, a practice of using ground-up mummified bones to soothe various ailments that was popular in 17th-century Western Europe; the infamous Donner Party pioneers who became trapped in the Sierra Nevada in 1846; ritual cannibalism that took place in Papua New Guinea until the 1950s; and famine-induced cannibalism in China in the 1960s.

Dr. Schutts book also features the story of the so-called Cannibal Cop, a former New York Police Department officer who was arrested in 2013 for participating in fetish forums that fantasized about cannibalizing women, and later acquitted. The New York Post has published more than 30 articles about the case, including one suggesting the Halloween costume of a policemans uniform with a severed hand on a plate.

Flavors of that saga can be found in the more recent accusations of sexual and physical abuse against the actor Armie Hammer, which have included that he allegedly sent cannibalistic messages to a romantic partner. Mr. Hammer has denied the accusations and, through his lawyer, declined to comment for this article.

After the allegations became public, he was dropped by his agency, checked into rehab and is now, Variety reports, selling time shares in the Cayman Islands. Coincidentally, Mr. Hammer worked with Mr. Chalamet and Mr. Guadagnino on Call Me by Your Name.

As to what may be fueling the desire for cannibalism stories today, Ms. Lyle, the Yellowjackets co-creator, said, I think that were obviously in a very strange moment. She listed the pandemic, climate change, school shootings and years of political cacophony as possible factors.

I feel like the unthinkable has become the thinkable, Ms. Lyle said, and cannibalism is very much squarely in that category of the unthinkable.

According to Ms. Summers, cannibalism is always symbolic. For her novels protagonist, eating human flesh can be seen as a way of holding on to a relationship that ended. For Ms. Summers herself, the plot of A Certain Hunger cant be uncoupled from my own personal experiences with disordered eating, with the tamping down of feminine appetites, the way the media chews up and spits out writers, bougie consumption and bougie lady consumption, she said.

More generally, Ms. Summers thinks that the recent spate of cannibalistic plots could also be commentaries on capitalism. Cannibalism is about consumption and its about burning up from the inside in order to exist, she said. Burnout is essentially over-consuming yourself, your own energy, your own will to survive, your sleep schedule, your eating schedule, your body.

Ms. Moshfegh said her theory was that it might be an antidote to the actual horror of whats happening to the planet. Like Ms. Summers, Ms. Moshfegh at times couldnt stomach her own work, describing the process of writing about cannibalism in Lapvona as a bit disturbing.

I had to think about what part of the body would be an interesting place to start, she said, and how it would feel to hold someones severed hand in yours.

The prop team on Yellowjackets had a similarly unnerving task in determining what to use as faux human flesh in the shows pilot episode.

Should it be the lab-grown human steak made from stem cells that spurred outrage at a London museum? The animal-free chicken, beef, salmon and dairy substitutes that some companies are creating using similar technology?

Ultimately, the prop team went with venison.

But theyll have to find an alternative for future episodes, Ms. Lyle and Mr. Nickerson said, because many in its cast are vegan.

Original post:
Why Are There so Many Books and Shows About Cannibalism? - The New York Times

Posted in New York Stem Cells | Comments Off on Why Are There so Many Books and Shows About Cannibalism? – The New York Times

Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 – Digital Journal

Posted: July 27, 2022 at 2:31 am

Market Overview

Thecell culture media marketis expected to cross USD 4.33 billion by 2027 at a CAGR of8.33%.

Market Dynamics

The markets growth is being fueled by a diverse range of cell culture media applications, increased research and development in the pharmaceutical industry, an increase in the prevalence of chronic diseases, and increased expansion and product launches by major players. Over the last few decades, advancements in cell culture technology have accelerated. It is widely regarded as one of the most dependable, robust, and mature technologies for biotherapeutic product development.

The high cost of cell culture media and the risk of contamination, on the other hand, are impeding the markets growth. However, the growing emphasis on regenerative and personalized medicine is likely to spur growth in the global cell culture media market.

Get Sample Report: https://www.marketresearchfuture.com/sample_request/4462

Competitive Dynamics

The notable players are the Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), GE Healthcare (US), Becton, Dickinson and Company (US), HiMedia Laboratories (India), Corning Incorporated (US), PromoCell (Germany), Sera Scandia A/S (Denmark), The Sartorius Group (Germany), and Fujifilm Holdings Corporation (Japan).

Segmental Analysis

The global market for cell culture media has been segmented according to product type, application, and end user.

The market has been segmented by product type into classical media, stem cell media, serum-free media, and others.

Further subcategories of stem cell culture media include bone marrow, embryonic stem cells, mesenchymal stem cells, and neural stem cells.

The market is segmented into four application segments: drug discovery and development, cancer research, genetic engineering, and tissue engineering and biochemistry.

The market is segmented by end user into biochemistry and pharmaceutical companies, research laboratories, academic institutions, and pathology laboratories.

Regional Overview

According to region, the global cell culture media market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas dominated the global cell culture media market. The large share is attributed to the presence of major manufacturers, rising disease prevalence resulting in increased demand for drugs and other medications, technological advancements in the preclinical and clinical segments, growing public awareness, and high disposable income.

Europe ranks second in terms of market size for cell culture media. Factors such as an increase in the biopharmaceutical sector in the European region, increased government initiatives to promote research to find a cure for the growing number of chronic diseases, an increase in the number of pharmaceutical manufacturers, improving economies, a high disposable income per individual, and increased healthcare spending are all contributing to the markets growth in this region. The European market is expected to be driven by expanding R&D activities and a developing biopharmaceutical sector.

Asia-Pacific held the third-largest market share, owing to the presence of numerous research organizations, low manufacturing costs, low labor costs, developing healthcare infrastructure, and increased investment by American and European market giants in Asian countries such as China and India.

The Middle East and Africa, with limited economic development and extremely low income, held the smallest market share in 2019 but is expected to grow due to growing public awareness and demand for improved healthcare facilities in countries, as well as rising disposable income.

Browse Full Reports: https://www.marketresearchfuture.com/reports/cell-culture-media-market-4462

Related Report: Dysmenorrhea Treatment Market Research Report- Global Forecast to 2027

Syringe and Needle Market Research Report Global Forecast to 2027

Global Medical Robotics Market Research Report- Forecast To 2027

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Here is the original post:
Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 - Digital Journal

Posted in New York Stem Cells | Comments Off on Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 – Digital Journal

Shai Efrati, MD, the World’s Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit – PR Web

Posted: July 27, 2022 at 2:31 am

Our new studies demonstrate something for the first time and its the holy grail of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time.

MIAMI (PRWEB) July 26, 2022

The Global Wellness Summit (GWS), the most prestigious conference on the $4.4 trillion business of wellness, announced today that Shai Efrati, MD, the worlds foremost research scientist on hyperbaric oxygen therapy, will keynote at the conference being held at the Hilton Tel Aviv from October 31 to November 3. Efrati is a professor at Sackler School of Medicine and the Sagol School of Neuroscience at Tel Aviv University and director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Centerthe largest hyperbaric center in the world, treating over 350 patients a day.

Efratis lab has created a unique approach for hyperbaric oxygen therapy (HBOT) which consists of immersing people in a high-pressure, high-oxygen environment and then carefully regulating oxygen and pressure levels. This technique, which is called the hyperoxic-hypoxic paradox (HHP), tricks the body into entering a regenerative state which unleashes a cascade of biological changes. These include the proliferation of stem cells, the generation of new blood vessels, and the repair of brain cells and tissue.

Eye-opening evidence:

Over the last decade, Efratis research team has authored dozens of high-quality clinical studies that show how this specific HBOT therapy revolving around the hyperoxic-hypoxic paradox has eye-opening impact on so many conditions. It can significantly boost brain function in stroke and traumatic brain injury patients, heal the wounds in the brain caused by PTSD, improve sexual function, and roll back the process of skin aging. This month, their randomized controlled trial found that the therapy incited brain healing and improved myriad symptoms in long Covid sufferers, an area where solutions have been elusive.

But its his recent research on healthy individuals that has such extraordinary implications for the wellness world. The therapy was recently shown to significantly improve (not just slow the loss of) cognitive function in healthy, older adults by generating new neurons and blood vessels in the brainthe first study to demonstrate that a brain can be made younger. Another recent study revealed that the treatment reversed two major processes associated with aging and its illnesses: the shortening of telomeres (the protective caps at the ends of every chromosome) and the accumulation of old, malfunctioning cells in the body. Participants telomeres were lengthened up to 38% while senescent cells saw a decrease of up to 37%.

Our new studies demonstrate something for the first time and its the holy grail of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time. Its analogous to the first time that man landed on the moon. After that first landing, everyone wanted to travel there, but even faster and more effectively. So, well see young scientists rush to study aging and huge investment in this area, said Efrati. Aging isnt a bad thing; its the functional decline that is. As the wellness world knows well, many more people seek solutions that can make them fully potent and active every single year of their life. The future is high-performance aging, and Im excited to share my vision of that futureand the rising place of hyperbaric oxygen therapy in the medical-wellness worldwith the leaders that will gather at the Summit.

Caution: This isnt the hyperbaric oxygen treatment at your corner spa:

Hyperbaric oxygen treatments are spawning at spas and wellness centers and with at-home products. But, as Efrati cautions, its not even the same approach: these offerings simply involve putting people in a sack, or pod, full of minimally pressurized, oxygenated air, when thats not what makes HBOT effective. The game-changing component is the hyperoxic-hypoxic paradox: the precise protocols weve optimized for oxygen and pressure levels, fluctuations, and durations that spark the regenerative process in the body, said Efrati. This evidence-based therapy has to be performed in a medical facility by a trained physician. All these oxygen spas and pods can be dangerous: they miss the quality assurance of the air pump being inside, and they pose threats of oxygen toxicity and other health issues. Theyre also not effective. The future is clearing up much confusion in the marketplace about what evidence-based hyperbaric oxygen therapy actually entails and achieves.

Aviv Clinics: Rolling out this evidence-based treatment globally:

To make a more powerful global impact and to walk faster, Efrati co-founded AVIV Scientific, a research organization and network of global medical-wellness clinics focused on innovative applications of hyperbaric medicine using the HHP protocols, that can increase cognitive and physical performance in healthy aging adults. Clinics are open in Tel Aviv, at The Villages in central Florida, and most recently in Dubaiand are expected to come to New York and the UK soon. Aviv plans 50 clinics around the world within the next decade. Each clinic combines HBOT with personalized medicine, cognitive and fitness training, and nutrition coaching. Thanks to an exclusive partnership with the worlds largest hyperbaric research facility, the Sagol Center at Shamir Medical Center, each patient's data and samples are sent to the centers large research lab, where blood, DNA, telomeres, MRI results, etc. are analyzed. Since Sagol Center is doing so much research, positive findings can immediately be implemented at the clinics. For instance, with their new trial indicating that HBOT can help with long Covid damage to the brain, new programs were quickly rolled out.

Every year we aim to bring the brightest stars in health and wellness to the stage, and Dr. Efrati is exactly the kind of innovator we seek: a dynamic thinker whose work will really shake up our future, whose solutions are grounded in evidence, and who understands that new connections between medicine and wellness lie ahead, said Susie Ellis, GWS chair and CEO. Its an incredible opportunity for delegates to be immersed in his research on the future of aging at such an early, pivotal moment. What hes doing is game-changing.

Registration for the 2022 Summit is now open.

About the Global Wellness Summit The Global Wellness Summit is the premier organization that brings together leaders and visionaries to positively shape the future of the $4.4 trillion global wellness economy. Its future-focused conference is held at a different global location each year and has traveled to the United States, Switzerland, Turkey, Bali, India, Morocco, Mexico, Austria, Italy and Singapore. GWS also hosts other virtual and in-person gatherings, including Wellness Master Classes, Wellness Sector Spotlights, Investor Reverse Pitch events and Global Wellness Symposiums. The organizations annual Global Wellness Trends Report offers expert-based predictions on the future of wellness. The 2022 Summit will be held in Tel Aviv, Israel from October 31 to November 3.

Share article on social media or email:

Continue reading here:
Shai Efrati, MD, the World's Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit - PR Web

Posted in New York Stem Cells | Comments Off on Shai Efrati, MD, the World’s Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit – PR Web

Herminia Pasantes revealed one of taurines big roles in the brain – Science News Magazine

Posted: July 27, 2022 at 2:31 am

When Herminia Pasantes Ordez was about 14 years old, in 1950, she heard her mother tell her father that she would never find a husband. Pasantes had to wear thick glasses for her poor eyesight. In her mothers eyes, those glasses meant her future as a good woman was doomed. This made my life easier, says Pasantes, because it was already said that I was going to study.

At a time when it was uncommon for women to become scientists, Pasantes studied biology at the National Autonomous University of Mexico in Mexico City, or UNAM. She was the first member of her family to go to college.

Headlines and summaries of the latest Science News articles, delivered to your inbox

Thank you for signing up!

There was a problem signing you up.

She became a neurobiologist and one of the most important Mexican scientists of her time. Her studies on the role of the chemical taurine in the brain offer deep insights into how cells maintain their size essential to proper functioning. In 2001, she became the first woman to earn Mexicos National Prize for Sciences and Arts in the area of physical, mathematical and natural sciences.

We basically learned about cell volume regulation through the eyes and work of Herminia, says Alexander Mongin, a Belarusian neuroscientist at Albany Medical College in New York.

Pasantes did get married, in 1965 while doing her masters in biochemistry at UNAM. She had a daughter in 1966 and a son in 1967 before starting a Ph.D. in natural sciences in 1970 at the Center for Neurochemistry at the University of Strasbourg in France. There, she worked in the laboratory of Paul Mandel, a Polish pioneer in neurochemistry.

The lab was trying to find out everything there was to know about the retina, the layer of tissue at the back of the eye that is sensitive to light. Pasantes decided to test whether free amino acids, a group that arent incorporated into proteins, were present in the retinas and brain of mice. Her first chromatography a lab technique that lets scientists separate and identify the components of a sample showed an immense amount of taurine in both tissues. Taurine would drive the rest of her scientific career, including work in her own lab, which she started around 1975 at the Institute of Cellular Physiology at UNAM.

Taurine turns out to be widely distributed in animal tissues and has diverse biological functions, some of which were discovered by Pasantes. Her research found that taurine helps maintain cell volume in nerve cells, and that it protects brain, muscle, heart and retinal cells by preventing the death of stem cells, which give rise to all specialized cells in the body.

Contrary to what most scientists had believed at the time, taurine didnt work as a neurotransmitter sending messages between nerve cells. Pasantes demonstrated for the first time that it worked as an osmolyte in the brain. Osmolytes help maintain the size and integrity of cells by opening up channels in their membranes to get water in or out.

Pasantes says she spent many years looking for an answer for why there is so much taurine in the brain. When you ask nature a question, 80 to 90 percent of the time, it responds no, she says. But when it answers yes, its wonderful.

Pasantes lab was one of the big four labs that did groundbreaking work on cell volume regulation in the brain, says Mongin.

Her work and that of others proved taurine has a protective effect; its the reason the chemical is today sprinkled in the containers that carry organs for transplants. Pasantes work was the foundation for our understanding of how to prevent and treat brain edema, a condition where the brain swells due to excessive accumulation of fluid, from head trauma or reduced blood supply, for example. She and other experts also reviewed the role of taurine for Red Bull, which added the chemical to its formula because of potentially protective effects in the heart.

Pasantes stopped doing research in 2019 and spends her time talking and writing about science. She hopes her story speaks to women around the world who wish to be scientists: It is important to send the message that it is possible, she says.

Years before she was accepted into Mandels lab, her application to a Ph.D. in biochemistry at the UNAM was rejected. Pasantes says the reason was that she had just had her daughter. Looking back, this moment was one of the most wonderful things that couldve happened to me, Pasantes says, because she ended up in Strasbourg, where her potential as a researcher bloomed.

Rosa Mara Gonzlez Victoria, a social scientist at the Autonomous University of the State of Hidalgo in Pachuca, Mexico, who specializes in gender studies, recently interviewed Pasantes for a book about Mexican women in science. Gonzlez Victoria thinks Pasantes response to that early rejection speaks to the kind of person she is: A woman that takes those nos and turns them into yess.

See more here:
Herminia Pasantes revealed one of taurines big roles in the brain - Science News Magazine

Posted in New York Stem Cells | Comments Off on Herminia Pasantes revealed one of taurines big roles in the brain – Science News Magazine

Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom… – The US Sun

Posted: July 27, 2022 at 2:31 am

A JOURNALIST revealed the chilling clue that disclosed her lover and famed surgeon as a "romance scammer."

Documentary producer Benita Alexander thought it was love when her job introduced her to internationally renowned surgeon Paolo Macchiarini.

5

5

5

5

Benita was pursuing a big story when the ill-fated lovers met in 2013.

A successful TV journalist, the single mother-of-one was interviewing him for a report on cutting-edge medicine.

"I was doing a story about regenerative medicine and his name kept coming up," Benita, a New York resident, said on the podcast Dr Death: Miracle Man.

Macchiarini had been credited with developing innovative surgical techniques using stem cells in synthetic trachea transplants.

They became friends and over time she felt herself falling for him, despite her journalistic integrity impeding the romance.

"He seemed like he was the miracle man," she said.

"He was a top doctor, he spoke six or seven languages.

"He was a good listener and gave me sage and solid advice."

In mid-2013, they became a couple and in December that year they became pre-engaged as Macchiarini, who lived in Barcelona, Spain, said he was still legally married with two children but had been separated for a long time and was filing for divorce.

It was eight months later when they became properly engaged after Macchiarini presented her with a $100K ring.

The couple had the wedding planned for July 2015.

"The headline is that it started out as a beautiful love story and it ended up as a total nightmare," said Benita.

"I, to this day, have no idea why he lied about our entire relationship."

Macchiarini and Benita quickly started planning an extravagant wedding, she said.

It was beyond Benita's wildest dreams - Macchiarini reportedly told her he invited Bill Clinton, Barack Obama, and Elton John, and that the Pope himself would oversee the ceremony.

It was at this point that Benita said she started to feel that something was not right.

After doing some digging, it transpired that Macchiarini was not the medical genius she thought he was.

In fact, the scientist was embroiled in lawsuits and accusations at work.

"I went full on into investigator mode as I knew he wouldnt tell me the truth," Benita said.

She found out exactly what hed lied about - and she said it was extensive.

He had told her, as personal surgeon to the Pope, the leader of the Catholic church wanted to marry the couple, she explained.

"He said he was having trouble finding a priest to marry us," she said.

"Then he said he had connections to the Vatican. It wasnt surprising being a surgeon in Italy.

"He [the Pope] wanted to use us as the poster couple for the Catholic church, to prove people who are divorced can get married in the Catholic church."

But Benita's intuition overtook her and she hired a private investigator to look into the surreal wedding.

"None of these people were coming," Benita said she tragically discovered.

"He didnt know Pope Francis, he wasnt his personal doctor."

The slip from "Prince Charming to pathological liar" took place over just two years, she said.

In July 2015 their "cat and mouse game" came to an end when she revealed to him everything she found through the private investigation.

"I put it all in a message. He responded wow,'" Benita claimed.

Macchiarini ran into some legal trouble regarding his stem cell treatments with Swedish prosecutors recently appealing a sentence given to the Italian surgeon, the Associated Press reported.

He was put on trial after his patients reportedly suffered bodily harm during his experimental surgeries but he always denied any criminal wrongdoing.

ABC News reported that Macchiarini has never spoken publicly about his relationship with Benita.

Benita and Macchiarini's wild relationship was featured in a special episode of ABC's 20/20 on Friday.

5

Here is the original post:
Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom... - The US Sun

Posted in New York Stem Cells | Comments Off on Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom… – The US Sun

Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans – VegNews

Posted: July 27, 2022 at 2:29 am

Cell-cultured seafood startup Pearlita Foods has successfully created the worlds first plant-based oyster prototype that looks and tastes just like a traditional oyster. The prototype is made using plant-based and cell-based technologies with a proprietary mushroom and seaweed base as well as Pearlitas novel flavor mixture that gives the oyster a pure, delicate, and authentic ocean taste and texture. The startup also plans to create biodegradable oyster shells that will impart the same experience as traditional oysters but remove the need for shucking, making it easier for consumers to serve and eat.

Earlier this year, Pearlita embarked on producing an alternative to oysters in an effort to meet the demand for ocean-derived delicacies using plant-based and cell-based technologies without harming the oceans. The startup will begin by rolling out its hybrid product while it continues to develop its cell lines for a line of fully cultured oysters. To cultivate oysters, Pearlita isolates cells from an oyster tissue sample, and with it, the startup is able to produce thousands of cultivated oysters.

While the startup continues its research and development on cultured oysters and biodegradable shells, Pearlita will debut its hybrid plant-based oyster using recycled oyster shells for its showcasing and tastings. In North Carolina, where Pearlita is headquartered, many coastal communities offer shell recycling drop-off locations to build new oyster reefs instead of disposing of the shells in landfills.

Pearlita Foods

According to Pearlita, over 85 percent of wild oyster reefs have been lost globally due to overfishing. Pearlita wants to change the seafood industry and it is striving to make cultivated oysters and other cell-based seafood commonplace so that traditional oysters can remain in the oceans and contribute to healthy ecosystems. Additionally, according to government advisories from the Centers for Disease Control and Prevention, ocean-derived bivalve shellfish such as clams, geoducks, mussels, scallops, and oysters can transmit norovirus to the people who eat them. These illness outbreaks are most often linked to oysters and can be deadly.

The startup aims to produce oysters with no reliance on the ocean or live animals, by using stem cells and bioreactors to produce cell-based oysters that are rich in flavor and nutrition. And because they are produced in a sterile environment, cultivated seafood is devoid of bacteria and virus contamination. Going forward, Pearlita plans to develop squid and scallop prototypes as well and work on scaling up production.

The cellular aquaculture startup recently secured investment from investment firm CULT Food Science to help scale its prototype. We are impressed by and proud of Pearlitas successful production of its first cultivated oyster prototype. Pearlitas commitment to making the world a better place and doing its part to increasing the worlds food security is encouraging as we possess the same goals, Lejjy Gafour, Chief Executive Officer of CULT, said in a statement. Pearlita is taking great steps to advance the production of cultured seafood on a mass scale. We are energized by the positive contributions that their team is making to the cellular agriculture industry.

Finless Foods

While Pearlita is focusing on developing ethical and sustainable seafood alternatives to ocean delicacies such as oysters, other food technology companies are tackling fish species such as tunawhich is the most consumed fish in the United States. Finless Foods is taking a similar approach to Pearlita by using plants and cultivated cells to make sustainable seafood, starting with tuna which will be available to restaurants and foodservice channels this year.

Earlier this year, Finless Foods showcased its plant-based tuna as part of a poke bowl and tacos served to guests at the Food Network & Cooking Channel South Beach Wine & Food Festival in Miami. The product is made from a blend of nine proprietary, plant-based ingredients that together mimic the texture and taste of sushi-grade tuna while also being able to withstand the addition of citrus and marinades.

Tuna plays an important role in ocean health and has historically been a difficult species for aquaculture, Finless Foods co-founder Brian Wyrwas said in a statement. We felt that developing viable alternatives would yield the greatest net impact for our ocean.

Other competitors in the cellular aquaculture space include San Diego-based BlueNalu, which is working to develop cell-based alternatives to fish, including yellowtail amberjack which it sampled in a private-tasting in 2019. In San Francisco, cellular aquaculture startup Wild Type is also working on growing sushi-grade meat made from a small amount of fish cells. Its pilot facility became operational in 2021 and Wild Type hopes to open an adjacent tasting restaurant where its cultivated fish can be showcased in traditional (but more sustainable) sushi preparations.

Over in Singapore, the countrys first cell-based seafood startup, Shiok Meats, is creating cultivated crab and lobster. Currently, Singapore is the only country in the world that allows the sale of cultivated meat. There, cultivated chicken made by GOOD Meat (a subsidiary of Eat Just) was approved for sale in December 2020.

For the latest vegan news, read:Chipotle Invested a $150 Million Funding Round For Vegan Steak StartupNavy Will Test Vegan Meat on at Least 2 US BasesCountry Crocks First Whipping Cream Is Made From Lentil Milk

Nicole Axworthy is the News Editor at VegNews and author of the cookbook DIY Vegan.

Happy birthday, VegNews! To celebrate, we're having a mega subscription salecomplete with incredible vegan prizes.

CHECK IT OUT

Happy birthday, VegNews! To celebrate, we're having a mega subscription salecomplete with incredible vegan prizes.

CHECK IT OUT

Visit link:
Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans - VegNews

Posted in North Carolina Stem Cells | Comments Off on Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans – VegNews

Dean Kamen on the power of celebrating your own obsoletion – Yahoo News

Posted: July 27, 2022 at 2:25 am

More than 40 years and 1,000 or so patents after selling his first company, AutoSyringe, to healthcare giant Baxter, Dean Kamen still gets a charge describing breakthrough innovation. It's been five years since his organ fabricating project ARMI (Advanced Regenerative Manufacturing Institute) divided critics.

The project made more waves early last month, at the CNN-hosted conference Life Itself. Kamen paints the picture appearing on a panel at TC Sessions: Robotics today:

Doris Taylor, who moved up here from where she spent more than a decade in Texas, at the Texas Heart Institute, she gets on stage with a beaker. In the beaker is a miniature, pediatric-scale beating heart that was manufactured with induced pluripotent stem cells were put into a scaffold of preexisting organ. Within an hour of that presentation, Martine Rothblatt, the founder and chairman of United Therapeutics, is on stage and they roll out from backstage an almost surrealistic, lit from the top of the box. A panel opens, and what emerges out of the top of this platform is a scaffold of a human lung, that was printed, entirely printed at the smallest scale any printer has ever operated.

Inventor Dean Kamen looks on as over 110,000 pounds of personal protective equipment (PPE), shipped from Shanghai, China, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020

Inventor Dean Kamen looks on as over 110,000 pounds of personal protective equipment (PPE), shipped from Shanghai, China, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020. The equipment will be used for medical workers and first responders in their fight against the virus outbreak. (AP Photo/Charles Krupa)

Kamen is first to admit, however, that the path to all success is paved with failure. The trick is learning the right lesson.

What I've learned from failure is go back and decide was the fundamental goal wrong -- that's why it failed, you succeeded, but nobody needs this -- or did the available technology and your systems integration and application have it wrong, in which case, you've now learned enough, go try again, go use a different approach, Kamen explains. Pick yourself up, try again, using a different approach. And it really doesn't matter how many times you fall down. If you fall down five times, but you stand up six, it's okay. And in the end, you only need a win every once in a while to keep your confidence up. And hopefully, to give you the resources to keep going even though inevitably you'll have failures, let the projects fail, don't let the people fail.

Story continues

[youtube https://www.youtube.com/watch?v=AjIISbARc20?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent&w=640&h=360%5D

These are among the fundamentals Kamen has attempted to infuse into FIRST, the education program he co-founded in 1989, with MIT professor Woodie Flowers. It is best known for its robotics competitions, which center around competitive builds of robots and other projects, bringing the teamwork and enthusiasm of sports to STEM education -- subjects that might otherwise turn off students who traditionally encounter them in more formal and staid settings.

Kids wont go to class, or theyll take math for 45 minutes between phonics and spelling, one day a week. But theyll go after school for three hourse, every single day to get better at football or get better at basketball. So I said, look, were not competing for the hearts and minds of kids with the science fair and the spelling bee, were competing with the things that they invest all of their time, energy and passion in. So lets use that model -- make it aspirational, make it after school. Dont give them quizzes and tests, give them letters and trophies. Bring the school band and the mascots.

U.S. Sen. Jeanne Shaheen (D-NH), right, looks toward inventor Dean Kamen as over 110,000 pounds of personal protective equipment (PPE) from Shanghai, China, delivered to protect medical workers and first responders fighting the COVID-19 virus outbreak, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020

U.S. Sen. Jeanne Shaheen (D-NH), right, looks toward inventor Dean Kamen as over 110,000 pounds of personal protective equipment (PPE) from Shanghai, China, delivered to protect medical workers and first responders fighting the COVID-19 virus outbreak, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020. (AP Photo/Charles Krupa)

Perhaps the hardest-fought lesson of all, however, is understanding, accepting and even welcoming the fact that progress in technology and sciences means that one day your best work will be eclipsed.

You have to be more than prepared for it. You have to be confident it will happen, and you have to celebrate it. I celebrate it more when its me that obsoleted the last thing I did, but if somebody else can obsolete it and if I get to a point where I need a better clinical solution than a dialysis machine or an insulin pump, if I can get to a place with somebody else's technology to gave me a new organ or a prosthetic limb or something, I need to have a better quality of life, I will thank that person. And I hope I will return that favor by giving them something of value that we invented.

[youtube https://www.youtube.com/watch?v=3rEVALfKbhA?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en-US&autohide=2&wmode=transparent&w=640&h=360%5D

Read more here:
Dean Kamen on the power of celebrating your own obsoletion - Yahoo News

Posted in New Hampshire Stem Cells | Comments Off on Dean Kamen on the power of celebrating your own obsoletion – Yahoo News

Page 319«..1020..318319320321..330340..»